11 results about "LRP5" patented technology

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

The application discloses a kind of nanobody specifically binding LRP5 and / or 6 and its application.The nanobody has the ability of selectively targeting and binding LRP5 and / or LRP6, wherein part of the antibody can inhibit the interaction of LRP5 and / or LRP6 with Wnt protein, thereby effectively inhibiting Wnt signaling pathway.The nanobody provided by the application can not only specifically recognize the co-receptor LRP5 and / or LRP6 of Wnt signaling pathway, but also show higher binding affinity, and can be widely applied in the detection of LRP5 and / or LRP6 and related research fields.

Disclosed are a nanobody that specifically binds to LRP5 and / or LRP6 and a use thereof. The nanobody has the ability to selectively target and bind to LRP5 and / or LRP6. Some antibodies can inhibit the interaction between LRP5 and / or LRP6 and Wnt proteins, thereby effectively suppressing the Wnt signaling pathway. The provided nanobody specifically recognizes co-receptors LRP5 and / or LRP6 of the Wnt signaling pathway, exhibits high binding affinity, and can be widely applied to the field of detection and related research of LRP5 and / or LRP6.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

The invention discloses a shark source single-domain antibody targeting LRP6 and application of the shark source single-domain antibody. The single-domain antibody has an amino acid sequence as shown in SEQ ID NO: 1, shows nanomole-level high affinity to LRP6 protein, has an affinity constant KD value of 1.8 * 10 <-9 > M, shows excellent physical and chemical stability, has a thermal denaturation temperature as high as 75.6 DEG C, and can still retain 92% or more of binding activity after being incubated for 2 hours under a strong acidic condition. Meanwhile, the antibody has high specificity, and the cross reaction rate of the antibody with homologous protein LRP5 and homologous protein LDLR is lower than 4%. The invention also provides a composition for reducing hypertension, hyperglycemia and hyperlipidemia, which contains the single-domain antibody and a specific natural plant extract composite component. Experiments show that the composition can synergistically act on a plurality of pathological links of the metabolic syndrome, the symptoms of hyperglycemia, hyperlipidemia and hypertension are remarkably improved in an animal model, the effect is better than that of a single component and a traditional control drug, and a brand new multi-target treatment scheme is provided for prevention and treatment of the metabolic syndrome.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

To provide a method for treating gastrointestinal disorders using a modified WNT agonist and a modulator of the WNT signaling pathway. [Solution] In one embodiment, the present disclosure includes an engineered WNT agonist comprising (a) one or more binding domains that bind to one or more FZDs; and (b) one or more binding domains that bind to LRP5, LRP6, or both LRP5 and LRP6, wherein the polypeptide sequence has at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to any of SEQ ID NOs: 1 to 18, or a polypeptide sequence disclosed in any one of SEQ ID NOs: 1 to 25, Figure 2, Figure 6, Table 1, or Table 3, or a functional fragment or variant thereof, for example, its binding fragment, for example, a VHH domain, a heavy chain variable domain, or a light chain variable domain.